The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2022 to 2030. Cervical cancer occurs in women in age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer which is sexually transmitted. Cervical cancer can be prevented by performing early screening test and vaccination using Gardasil against HPV infection.
It is quite obvious that generic market is having the major economic share in the cervical cancer treatment market, however the advent of biologics in the form of monoclonal antibodies and biosimilars has resulted in a major paradigm shift in the treatment regimen. Z-100 and ADXS11-001 are currently in the phase III clinical trials being tested for drug safety and efficacy in the treatment of cervical cancer.
Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are, Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F.Hoffman La-Roche AG, GlaxoSmithkline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
It is quite obvious that generic market is having the major economic share in the cervical cancer treatment market, however the advent of biologics in the form of monoclonal antibodies and biosimilars has resulted in a major paradigm shift in the treatment regimen. Z-100 and ADXS11-001 are currently in the phase III clinical trials being tested for drug safety and efficacy in the treatment of cervical cancer.
Affordable reimbursement scenario drive the chemotherapy market growth
Currently, chemotherapy is reigning the product segment for cervical cancer treatment market. Drugs such as cisplatin, carboplatin, paclitaxel, doxorubicin and gemcitabine are employed for the treatment of cervical cancer in advanced stages. Radiation therapy such as external beam therapy and brachytherapy are given concurrently with chemotherapy in some stages of cervical cancer to give excellent synergistic effect. The side effects associated with both the therapy are severe thereby leading to the need for targeted drug therapy. Avastin (bevacizumab) and Keytruda (pembrolizumab) etc. are used in cancer immunotherapy which possesses impressive clinical efficacy, dose tolerance and patient compliance. Targeted drug therapy will be the fastest growing market during the forecast period owing to the strong drug pipeline in phase III clinical trials such as nimotuzumab and Atezolizumab. Cervical hysterectomy involves the removal of uterus, cervix and sometimes the fallopian tubes in women suffering with early stage cervical cancer.Increasing number of patients screened for cervical cancer drive the market growth in North America
North America is the clear leader for the geographical segment in the cervical cancer treatment market. As per the latest research findings of American Cancer Society, in 2019, approximately 13,170 new cases were diagnosed for cervical cancer and around 4,250 women will die from cervical cancer. Rising prevalence of cervical cancer and increasing public health awareness resulting in early screening and medical intervention drives the market growth in North America. According to the facts presented by World Health Organization (WHO) it is estimated that in 25,000 women for the European region will die from cervical cancer. Existence of major players such as Merck & Co., Inc., F.Hoffman La-Roche AG, GlaxoSmithkline Plc., etc. propel the cervical cancer market growth in the European region. Asia Pacific will register outstanding growth during the forecast period owing to the proactive government policies in early screening and medical intervention to curb the mortality related to cervical cancer and presence of huge generic market.Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are, Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F.Hoffman La-Roche AG, GlaxoSmithkline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cervical Cancer Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Cervical Cancer Treatment market and their expected impact during the forecast period.
Market Segmentation
Product
- Chemotherapy
- Targeted Therapy
- Surgical Procedure
- Radiation Therapy
- Others
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Cervical Cancer Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Cervical Cancer Treatment market?
- Which is the largest regional market for Cervical Cancer Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Cervical Cancer Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Cervical Cancer Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Cervical Cancer Treatment Market
2.2. Global Cervical Cancer Treatment Market, By Product, 2021 (US$ Million)
2.3. Global Cervical Cancer Treatment Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Cervical Cancer Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Cervical Cancer Treatment Market Vendors
3.2. Strategies Adopted by Cervical Cancer Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Cervical Cancer Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Cervical Cancer Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Chemotherapy
5.3.2. Targeted Therapy
5.3.3. Surgical Procedure
5.3.4. Radiation Therapy
5.3.5. Others
6. North America Cervical Cancer Treatment Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
6.3.Cervical Cancer Treatment Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
7. UK and European Union Cervical Cancer Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
7.3.Cervical Cancer Treatment Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
8. Asia Pacific Cervical Cancer Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
8.3.Cervical Cancer Treatment Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
9. Latin America Cervical Cancer Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
9.3.Cervical Cancer Treatment Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
10. Middle East and Africa Cervical Cancer Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
10.3.Cervical Cancer Treatment Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Cervical Cancer Treatment Market: By Product, 2020-2030, USD (Million)
11. Company Profile
11.1. Allergan, Plc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Biocon Ltd.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. CooperSurgical, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Eli Lilly & Company
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. F.Hoffman La-Roche AG
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. GlaxoSmithKline, Plc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Ethicon, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Merck & Co., Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Teva Pharmaceutical Industries Ltd.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Varian Medical Systems, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
List of Figures
Figure 1 Global Cervical Cancer Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Cervical Cancer Treatment Market: Quality Assurance
Figure 5 Global Cervical Cancer Treatment Market, By Product, 2021
Figure 6 Global Cervical Cancer Treatment Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Cervical Cancer Treatment Market, 2021
Figure 8 Market Positioning of Key Cervical Cancer Treatment Market Players, 2021
Figure 9 Global Cervical Cancer Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Cervical Cancer Treatment Market, By Product, 2021 Vs 2030, %
Figure 11 U.S. Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 12 Canada Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 14 UK Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 15 Germany Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 16 Spain Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 17 Italy Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 18 France Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 20 China Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 21 Japan Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 22 India Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 23 Australia Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 24 South Korea Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 26 Brazil Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 27 Mexico Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 29 GCC Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 30 Africa Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Cervical Cancer Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 2 North America Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 3 U.S. Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 4 Canada Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 5 Rest of North America Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 6 UK and European Union Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 7 UK Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 8 Germany Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 9 Spain Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 10 Italy Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 11 France Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 12 Rest of Europe Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 13 Asia Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 14 China Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 15 Japan Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 16 India Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 17 Australia Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 18 South Korea Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 19 Latin America Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 20 Brazil Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 21 Mexico Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 22 Rest of Latin America Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 23 Middle East and Africa Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 24 GCC Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 25 Africa Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Cervical Cancer Treatment Market By Product, 2020-2030, USD (Million)
Companies Mentioned
- Allergan Plc.
- Biocon Ltd.
- CooperSurgical Inc.
- Eli Lilly & Company
- F.Hoffman La-Roche AG
- GlaxoSmithkline Plc.
- Ethicon Inc.
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- Varian Medical Systems Inc.
